1
|
Palmquist KB, Truver MT, Shoff EN, Krotulski AJ, Swortwood MJ. Review of analytical methods for screening and quantification of fentanyl analogs and novel synthetic opioids in biological specimens. J Forensic Sci 2023; 68:1643-1661. [PMID: 37221651 DOI: 10.1111/1556-4029.15282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 04/24/2023] [Accepted: 05/05/2023] [Indexed: 05/25/2023]
Abstract
Fentanyl, fentanyl analogs, and other novel synthetic opioids (NSO), including nitazene analogs, prevail in forensic toxicology casework. Analytical methods for identifying these drugs in biological specimens need to be robust, sensitive, and specific. Isomers, new analogs, and slight differences in structural modifications necessitate the use of high-resolution mass spectrometry (HRMS), especially as a non-targeted screening method designed to detect newly emerging drugs. Traditional forensic toxicology workflows, such as immunoassay and gas chromatography mass spectrometry (GC-MS), are generally not sensitive enough for detection of NSOs due to observed low (sub-μg/L) concentrations. For this review, the authors tabulated, reviewed, and summarized analytical methods from 2010-2022 for screening and quantification of fentanyl analogs and other NSOs in biological specimens using a variety of different instruments and sample preparation approaches. Limits of detection or quantification for 105 methods were included and compared to published standards and guidelines for suggested scope and sensitivity in forensic toxicology casework. Methods were summarized by instrument for screening and quantitative methods for fentanyl analogs and for nitazenes and other NSO. Toxicological testing for fentanyl analogs and NSOs is increasingly and most commonly being conducted using a variety of liquid chromatography mass spectrometry (LC-MS)-based techniques. Most of the recent analytical methods reviewed exhibited limits of detection well below 1 μg/L to detect low concentrations of increasingly potent drugs. In addition, it was observed that most newly developed methods are now using smaller sample volumes which is achievable due to the sensitivity increase gained by new technology and new instrumentation.
Collapse
Affiliation(s)
| | - Michael T Truver
- Forensic Toxicology Laboratory, Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida, USA
| | - Elisa N Shoff
- Miami-Dade Medical Examiner Department, Miami, Florida, USA
| | - Alex J Krotulski
- Center for Forensic Science Research and Education, Fredric Rieders Family Foundation, Willow Grove, Pennsylvania, USA
| | - Madeleine J Swortwood
- Department of Forensic Science, Sam Houston State University, Huntsville, Texas, USA
| |
Collapse
|
2
|
Uljon S. Advances in fentanyl testing. Adv Clin Chem 2023; 116:1-30. [PMID: 37852717 DOI: 10.1016/bs.acc.2023.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2023]
Abstract
Fentanyl is a synthetic opioid that was approved by the FDA in the late 1960s. In the decades since, non-prescription use of fentanyl, its analogs, and structurally unrelated novel synthetic opioids (NSO) has become a worsening public health crisis. There is a clear need for accessible testing for these substances in biological specimens and in apprehended drugs. Immunoassays for fentanyl in urine are available but their performance is restricted to facilities that hold moderate complexity laboratory licenses. Immunoassays for other matrices such as oral fluid (OF), blood, and meconium have been developed but are not widely available. Point of care tests (POCT), such as lateral flow immunoassays or fentanyl test strips (FTS), are widely available but not approved by the FDA for clinical use. All immunoassays are vulnerable to false positive and false negative results. Immunoassays may or may not be able to detect fentanyl analogs and NSOs. Mass spectrometry (MS) can accurately and reliably measure fentanyl and its major metabolite norfentanyl in urine and oral fluid. MS is available at reference laboratories and large hospitals. Liquid chromatography paired with tandem mass spectrometry (LC-MS/MS) is the most widely used method and has outstanding specificity and sensitivity for fentanyl and norfentanyl. When compared to immunoassays, MS is more expensive, requires more technical skill, and takes longer to result. Newer mass spectrometry methods can measure fentanyl analogs and NSO. Both mass spectrometry assays and immunoassays [in the form of fentanyl test strips (FTS)] have potential use in harm reduction programs.
Collapse
Affiliation(s)
- Sacha Uljon
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
| |
Collapse
|
3
|
Gao J, Xu B, Yang R, Zhang H. Screening strategy for ketamine-based new psychoactive substances using fragmentation characteristics from high resolution mass spectrometry. Forensic Sci Int 2023; 347:111677. [PMID: 37028217 DOI: 10.1016/j.forsciint.2023.111677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 03/29/2023] [Accepted: 04/03/2023] [Indexed: 04/08/2023]
Abstract
Recreational designer drugs called new psychoactive substances (NPS) are emerging and pose enormous risks to public health. Detection of recently discovered or unreported NPS remains a huge challenge by using traditional targeted mass spectrometry methods. Here a novel screening strategy was developed to detect both known and novel analogs of NPS based on fragmentation characteristics from liquid chromatography-high resolution mass spectrometry (LC-HRMS). The HRMS fragmentation pathway of one selected NPS family was investigated to form a database containing predicted drugs as well as their mass characteristics. During the study, an unexpected substituent effect was found to distinguish geometric isomers. Seventy-eight seized samples were analyzed using this strategy, four ketamine-based NPS were detected and three of them were newly marketed. The substituent effect predicted the position of their phenylic substituent, the results were confirmed by NMR.
Collapse
|
4
|
Zhang Y, Halifax JC, Tangsombatvisit C, Yun C, Pang S, Hooshfar S, Wu AH, Lynch KL. Development and application of a High-Resolution mass spectrometry method for the detection of fentanyl analogs in urine and serum. J Mass Spectrom Adv Clin Lab 2022; 26:1-6. [PMID: 36065325 PMCID: PMC9440429 DOI: 10.1016/j.jmsacl.2022.07.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 07/13/2022] [Accepted: 07/20/2022] [Indexed: 11/30/2022] Open
Abstract
Utilization of the fentanyl analog screening kit from the Centers for Disease ControlDevelopment of a fentanyl analog high resolution mass spectrometry library. Fentanyl analogs are rarely identified without the co-occurrence of fentanyl. Fentanyl analogs fragmentation occurs at two specific bonds generating two dominate ions.
Introduction The use of illicitly manufactured synthetic opioids, specifically fentanyl and its analogs, has escalated exponentially in the United States over the last decade. Due to the targeted nature of drug detection methods in clinical laboratories and the ever-evolving list of synthetic opioids of concern, alternative analytical approaches are needed. Methods Using the fentanyl analog screening (FAS) kit produced by the Centers for Disease Control and Prevention (CDC), we developed a liquid chromatography-high resolution mass spectrometry (LC-HRMS) synthetic opioid spectral library and data acquisition method using information dependent acquisition of product ion spectra. Chromatographic retention times, limits of detection and matrix effects, in urine and serum, for the synthetic opioids in the FAS kit (n = 150) were established. All urine and serum specimens sent to a clinical toxicology laboratory for comprehensive drug testing in 2019 (n = 856) and 2021 (n = 878) were analyzed with the FAS LC-HRMS library to determine the prevalence of fentanyl analogs and other synthetic opioids, retrospectively (2019) and prospectively (2021). Results The limit of detection (LOD) of each opioid ranged from 1 to 10 ng/mL (median, 2.5 ng/mL) in urine and 0.25–2.5 ng/mL (median, 0.5 ng/mL) in serum. Matrix effects ranged from −79 % to 86 % (median, −37 %) for urine, following dilution and direct analysis, and −80 % to 400 % (median, 0 %) for serum, following protein precipitation. The prevalence of fentanyl/fentanyl analogs in serum samples increased slightly from 2019 to 2021 while it remained the same in urine. There were only 2 samples identified that contained a fentanyl analog without the co-occurrence of fentanyl or fentanyl metabolites. Analysis of the established MS/MS spectral library revealed characteristic fragmentation patterns in most fentanyl analogs, which can be used for structure elucidation and drug identification of future analogs. Conclusions The LC-HRMS method was capable of detecting fentanyl analogs in routine samples sent for comprehensive drug testing. The method can be adapted to accommodate testing needs for the evolving opioid epidemic.
Collapse
Affiliation(s)
- Yu Zhang
- Department of Laboratory Medicine, University of California, San Francisco, and Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, ZSFG Bldg. 5, 2M16 San Francisco, CA 94110, USA
| | - John C. Halifax
- Department of Laboratory Medicine, University of California, San Francisco, and Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, ZSFG Bldg. 5, 2M16 San Francisco, CA 94110, USA
| | | | - Cassandra Yun
- Department of Laboratory Medicine, University of California, San Francisco, and Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, ZSFG Bldg. 5, 2M16 San Francisco, CA 94110, USA
| | - Shaokun Pang
- SCIEX, 1201 Radio Rd, Redwood City, CA 94065, USA
| | - Shirin Hooshfar
- Department of Laboratory Medicine, University of California, San Francisco, and Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, ZSFG Bldg. 5, 2M16 San Francisco, CA 94110, USA
| | - Alan H.B. Wu
- Department of Laboratory Medicine, University of California, San Francisco, and Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, ZSFG Bldg. 5, 2M16 San Francisco, CA 94110, USA
| | - Kara L. Lynch
- Department of Laboratory Medicine, University of California, San Francisco, and Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, ZSFG Bldg. 5, 2M16 San Francisco, CA 94110, USA
- Corresponding author.
| |
Collapse
|
5
|
Yang D, Zheng Q, Ahmed F, Parat MO, Tscharke BJ. A simple liquid extraction for simultaneous determination of 12 opioid ligands in plasma by LC-MS/MS. ANALYTICAL METHODS : ADVANCING METHODS AND APPLICATIONS 2022; 14:1523-1528. [PMID: 35352730 DOI: 10.1039/d1ay01631h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Opioids are commonly used as analgesics to relieve chronic pain and have high abuse potential. Due to their strong potency and trace concentration in plasma, a robust analytical method is necessary for quantification in forensic and pharmacology fields. Hence, this study developed and validated a simple, rapid, and robust method for the simultaneous determination of 12 opioids and metabolites which were available legally by prescription or abused for non-medical purposes, in plasma samples by simple liquid extraction and high-performance liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). We compared the extraction recovery of our sample pre-treatment to two other sample pre-treatments (namely QuEChERS and simplified QuEChERS) and showed that the method used in our study gave the highest recoveries. The method validation followed the European Medicines Agency guidelines, including selectivity, carryover, accuracy and precision, dilution integrity, matrix effect and freeze/thaw stability. This method's accuracy ranged from 85% to 115% with a precision less than 15%, within the acceptable range of the validation protocol. The lower limit of quantification of the method ranged between 0.05 μg L-1 and 0.38 μg L-1 among 12 opioids/metabolites. Stability was assessed, with all opioids observed as relatively stable at 0.5 μg L-1 and 5 μg L-1 levels under -20 °C and 25 °C storage conditions. In summary, the developed method has the potential to achieve simultaneous analysis for monitoring opioids in forensic and pain management regimens using a simple sample pre-treatment.
Collapse
Affiliation(s)
- Dan Yang
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, China.
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba, Queensland 4102, Australia
| | - Qiuda Zheng
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba, Queensland 4102, Australia
| | - Fahad Ahmed
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba, Queensland 4102, Australia
| | - Marie-Odile Parat
- School of Pharmacy, The University of Queensland, 20 Cornwall Street, Woolloongabba, Queensland 4102, Australia
| | - Benjamin J Tscharke
- Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba, Queensland 4102, Australia
| |
Collapse
|
6
|
Klingberg J, Keen B, Cawley A, Pasin D, Fu S. Developments in high-resolution mass spectrometric analyses of new psychoactive substances. Arch Toxicol 2022; 96:949-967. [PMID: 35141767 PMCID: PMC8921034 DOI: 10.1007/s00204-022-03224-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 01/12/2022] [Indexed: 11/17/2022]
Abstract
The proliferation of new psychoactive substances (NPS) has necessitated the development and improvement of current practices for the detection and identification of known NPS and newly emerging derivatives. High-resolution mass spectrometry (HRMS) is quickly becoming the industry standard for these analyses due to its ability to be operated in data-independent acquisition (DIA) modes, allowing for the collection of large amounts of data and enabling retrospective data interrogation as new information becomes available. The increasing popularity of HRMS has also prompted the exploration of new ways to screen for NPS, including broad-spectrum wastewater analysis to identify usage trends in the community and metabolomic-based approaches to examine the effects of drugs of abuse on endogenous compounds. In this paper, the novel applications of HRMS techniques to the analysis of NPS is reviewed. In particular, the development of innovative data analysis and interpretation approaches is discussed, including the application of machine learning and molecular networking to toxicological analyses.
Collapse
Affiliation(s)
- Joshua Klingberg
- Australian Racing Forensic Laboratory, Racing NSW, Sydney, NSW, 2000, Australia.
| | - Bethany Keen
- Centre for Forensic Science, University of Technology Sydney, Broadway, NSW, 2007, Australia
| | - Adam Cawley
- Australian Racing Forensic Laboratory, Racing NSW, Sydney, NSW, 2000, Australia
| | - Daniel Pasin
- Section of Forensic Chemistry, Department of Forensic Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Shanlin Fu
- Centre for Forensic Science, University of Technology Sydney, Broadway, NSW, 2007, Australia
| |
Collapse
|
7
|
Delaney SR, Tacker DH, Snozek CLH. The North American opioid epidemic: opportunities and challenges for clinical laboratories. Crit Rev Clin Lab Sci 2022; 59:309-331. [PMID: 35166639 DOI: 10.1080/10408363.2022.2037122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Since 1999, the opioid epidemic in North America has resulted in over 1 million deaths, and it continues to escalate despite numerous efforts in various arenas to combat the upward trend. Clinical laboratories provide drug testing to support practices such as emergency medicine, substance use disorder treatment, and pain management; increasingly, these laboratories are collaborating in novel partnerships including drug-checking services (DCS) and multidisciplinary treatment teams. This review examines drug testing related to management of licit and illicit opioid use, new technologies and test strategies employed by clinical laboratories, barriers hindering laboratory response to the opioid epidemic, and areas for improvement and standardization within drug testing. Literature search terms included combinations of "opioid," "opiate," "fentanyl," "laboratory," "epidemic," "crisis," "mass spectrometry," "immunoassay," "drug screen," "drug test," "guidelines," plus review of PubMed "similar articles" and references within publications. While immunoassay (IA) and point-of-care (POC) test options for synthetic opioids are increasingly available, mass spectrometry (MS) platforms offer the greatest flexibility and sensitivity for detecting novel, potent opioids. Previously reserved as a second-tier application in most drug test algorithms, MS assays are gaining a larger role in initial screening for specific patients and DCS. However, there are substantial differences among laboratories in terms of updating test menus, algorithms, and technologies to meet changing clinical needs. While some clinical laboratories lack the resources and expertise to implement MS, many are also slow to adopt available IA and POC tests for newer opioids such as fentanyl. MS-based testing also presents challenges, including gaps in available guidance for assay validation and ongoing performance assessment that contribute to a dramatic lack of standardization among laboratories. We identify opportunities for improvement in laboratory operations, reporting, and interpretation of drug test results, including laboratorian and provider education and laboratory-focused guidelines. We also highlight the need for collaboration with providers, assay and instrument manufacturers, and national organizations to increase the effectiveness of clinical laboratory and provider efforts in preventing morbidity and mortality associated with opioid use and misuse.
Collapse
Affiliation(s)
- Sarah R Delaney
- Department of Laboratory Medicine, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.,Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada
| | - Danyel H Tacker
- Department of Pathology, Anatomy, and Laboratory Medicine, West Virginia University School of Medicine, Morgantown, WV, USA
| | - Christine L H Snozek
- Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ, USA
| |
Collapse
|
8
|
DONG Z, YANG C, XU T, DAI D, GAO L, YANG L, WANG Q. [Analysis of 29 fentanyl analogs and their fragmentation mechanism by liquid chromatography-quadrupole time-of-flight mass spectrometry]. Se Pu 2022; 40:28-40. [PMID: 34985213 PMCID: PMC9404147 DOI: 10.3724/sp.j.1123.2021.01036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Indexed: 11/25/2022] Open
Abstract
Given the wide variety of fentanyl analogs, the test for this entire group tends to be crucial and particularly difficult since all fentanyl-like substances are listed as controlled substances in China. This study meticulously analyzed the fragmentation pathways and mechanisms of 29 fentanyl analogs and summarized the fragmentation pathways and features for the entire group of fentanyl analogs, thus providing a reference for related screening tests. Fentanyl, thiofentanyl, and sufentanil were selected as the representative compounds in this study, and the fragmentation mechanism of their fragment ions was interpreted. The general fragmentation rules for fentanyl analogs were summarized as well. The fragment ions of the three compounds formed by induced cleavage (i) came with high abundance ratios, such as fragment ions of m/z 188, 105, 194, 111, and 238, while the induced cleavage was due to the amide and piperidinyl groups. Moreover, the induction ability of amide group was significantly stronger than that of the piperidinyl group, and induced cleavage was the main fragmentation pathway for most of the fentanyl analogs. Furthermore, the fragment ions with m/z 281 and 287 for fentanyl and thiofentanyl were formed by loss of the propionyl group after single H rearrangement (rH). The fragment ions with m/z 216, 146, and 132 for fentanyl and thiofentanyl were formed by double H rearrangement (r2H). Although their abundance ratios were not high, they still had specificity and regularity. Elimination reaction (re) was also a very common fragmentation pathway for these compounds, leading to fragment ions with m/z 134 and 140. Phenylethyl substituents were more prone to the elimination reaction with a higher abundance ratio than thiophenethyl substituents. Compounds such as sufentanil with methoxy substituents at the piperidinyl para-position could produce a large number of fragment ions, which were more susceptible to the rH pathway and loss of methanol neutral molecules, leading to the formation of ions with m/z 355. Similarly, compounds such as remifentanil bearing a methyl formate substituent at the piperidine para-position also produced numerous fragment ions, which were more prone to the rH pathway to lose methyl formate or methanol neutral molecules and furnish fragment ions with m/z 317 or 345. Compounds containing hydroxyl substituents, such as β-hydroxyfentanyl and β-hydroxythiofentanyl, produce significant dehydration ions and formed fragment ions with m/z 335 (β-hydroxyfentanyl) and m/z 341 (β-hydroxythiofentanyl). A method based on liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) for the qualitative and quantitative determination of the 29 fentanyl analogs was developed. Drugs and white powder samples were extracted by acetonitrile, as well as protein and milk beverage samples. Sugar-containing solids or powders, drinking water, fruit and vegetable drinks, health drinks, tea drinks, and alcohol samples were extracted by 10% acetonitrile aqueous solution. Following vortexing, centrifugation, and membrane separation, the target compounds were separated on a Kinetex C18 column (100 mm×2.1 mm, 2.6 μm) with gradient elution at a flow rate of 0.4 mL/min. The mobile phases were composed of acetonitrile and 0.08% formic acid aqueous solution. The target compounds were quantified by LC-QTOF-MS using an external standard method in positive ion mode. The 29 fentanyl analogs showed good linear relationships in the range of 1-20 μg/L, and the correlation coefficients were greater than 0.995. The limits of detection (LODs) and limits of quantification (LOQs) were 0.01 mg/kg and 0.05, respectively. The average recoveries were 85.2%-112.9% for hypoglycemic drugs, Lulu drinks, glucose powder, Zhenlu health drink and chocolate, with RSDs of 1.9%-19.8% (n=6). This method is rapid, simple, time-saving, highly sensitivity and stable, and it is applicable to a wide variety of samples. Hence, it is suitable for the identification, confirmation, and quantitative detection of the 29 fentanyl analogs in drugs, solids or powders containing sugar, beverages, drinking water, wine samples, etc.
Collapse
Affiliation(s)
- Zhenlin DONG
- 大连海关技术中心, 辽宁 大连 116001
- Technical Center of Dalian Customs, Dalian 116001, China
| | - Chunguang YANG
- 大连海关技术中心, 辽宁 大连 116001
- Technical Center of Dalian Customs, Dalian 116001, China
| | - Tian XU
- 大连海关技术中心, 辽宁 大连 116001
- Technical Center of Dalian Customs, Dalian 116001, China
| | - Di DAI
- 大连海关技术中心, 辽宁 大连 116001
- Technical Center of Dalian Customs, Dalian 116001, China
| | - Lu GAO
- 大连海关技术中心, 辽宁 大连 116001
- Technical Center of Dalian Customs, Dalian 116001, China
| | - Lu YANG
- 大连海关技术中心, 辽宁 大连 116001
- Technical Center of Dalian Customs, Dalian 116001, China
| | - Qiuyan WANG
- 大连海关技术中心, 辽宁 大连 116001
- Technical Center of Dalian Customs, Dalian 116001, China
| |
Collapse
|
9
|
Swanson KD, Shaner RL, Krajewski LC, Bragg WA, Johnson RC, Hamelin EI. Use of Diagnostic Ions for the Detection of Fentanyl Analogs in Human Matrices by LC-QTOF. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2021; 32:2852-2859. [PMID: 34793156 PMCID: PMC10955423 DOI: 10.1021/jasms.1c00267] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
To combat the ongoing opioid epidemic, our laboratory has developed and evaluated an approach to detect fentanyl analogs in urine and plasma by screening LC-QTOF MS/MS spectra for ions that are diagnostic of the core fentanyl structure. MS/MS data from a training set of 142 fentanyl analogs were used to select the four product ions and six neutral losses that together provided the most complete coverage (97.2%) of the training set compounds. Furthermore, using the diagnostic ion screen against a set of 49 fentanyl analogs not in the training set resulted in 95.9% coverage of those compounds. With this approach, lower reportable limits for fentanyl and a subset of fentanyl-related compounds range from 0.25 to 2.5 ng/mL in urine and 0.5 to 5.0 ng/mL in plasma. This innovative processing method was applied to evaluate simulated exposure samples of remifentanil and carfentanil in water and their metabolites remifentanil acid and norcarfentanil in urine. This flexible approach enables a way to detect emerging fentanyl analogs in clinical samples.
Collapse
Affiliation(s)
- Kenneth D. Swanson
- Division of Laboratory Sciences, National Center for Environmental Health, CDC, Atlanta, GA 30341
| | - Rebecca L. Shaner
- Division of Laboratory Sciences, National Center for Environmental Health, CDC, Atlanta, GA 30341
| | - Logan C. Krajewski
- Division of Laboratory Sciences, National Center for Environmental Health, CDC, Atlanta, GA 30341
| | - William A. Bragg
- Division of Laboratory Sciences, National Center for Environmental Health, CDC, Atlanta, GA 30341
| | - Rudolph C. Johnson
- Division of Laboratory Sciences, National Center for Environmental Health, CDC, Atlanta, GA 30341
| | - Elizabeth I. Hamelin
- Division of Laboratory Sciences, National Center for Environmental Health, CDC, Atlanta, GA 30341
| |
Collapse
|
10
|
Palmquist KB, Swortwood MJ. Long-Term Stability of 13 Fentanyl Analogs in Blood. J Anal Toxicol 2021; 45:870-877. [PMID: 34008837 DOI: 10.1093/jat/bkab051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 04/26/2021] [Accepted: 05/18/2021] [Indexed: 12/18/2022] Open
Abstract
Fentanyl analogs continue to play a major role in proliferating the opioid epidemic in the United States. With high rates of overdose deaths, forensic laboratories experience backlogs, which may lead to false negative results due to drug instability. To address this issue, a quantitative method was validated for fentanyl analogs (3-methylfentanyl, 4-ANPP, 4-fluoro-isobutyrylfentanyl (4-FIBF), acetylfentanyl, acrylfentanyl, butyrylfentanyl, carfentanil, cyclopropylfentanyl, fentanyl, furanylfentanyl, methoxyacetylfentanyl, p-fluorofentanyl, and valerylfentanyl) in blood using liquid chromatography-quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS) and used to assess long-term stability under various temperature conditions (-20°C, 4°C, ~25°C, and 35°C) for 9 months. Authentic specimens were also analyzed 6 months apart for applicability to postmortem blood. Method validation resulted in calibration ranges of 1-100 ng/mL and limits of detection (LOD) of 0.5 ng/mL. Precision and bias were acceptable (within ±7.2%CV and ±15.2%, respectively). Matrix effects exhibited ion enhancement for all analytes, except carfentanil and 4-ANPP in low quality control (>25%). For long-term stability, fentanyl analogs (except acrylfentanyl) remained stable under room temperature and refrigerated conditions at low and high concentrations (81.3-112.5% target) for 9 months. While most fentanyl analogs remained stable frozen, degradation was observed after 2 weeks (4 freeze/thaw cycles). At elevated temperatures, most analytes were stable for 1 week (74.2-112.6% target). Acrylfentanyl was unstable after 24h under elevated (70% loss) and room temperatures (53-60% loss), 48-72h refrigerated (28-40% loss), and 4 weeks frozen (22% loss). In authentic bloods (n=7), initial furanylfentanyl (FuF) and 4-ANPP concentrations were 1.1-3.6 and 1.4-6.4 ng/mL, respectively. Percent loss of FuF and 4-ANPP over 6 months were 16.3-37.4% and 0.2-26.8%, respectively. Samples suspected to contain fentanyl analogs are recommended to be stored refrigerated or frozen with limited freeze/thaw cycles. Due to instability, in the event of an acrylfentanyl overdose, samples should be analyzed immediately or stored frozen with analysis within 1 month.
Collapse
Affiliation(s)
| | - Madeleine J Swortwood
- Department of Forensic Science, College of Criminal Justice, Sam Houston State University, 1003 Bowers Blvd, Huntsville, TX 77341, USA
| |
Collapse
|
11
|
Wang H, Zhao X, Shang Y, Wang H, Wang P, Yu X. Quantitative analysis of 20 fentanyl analogues by modified QuEChERS-LC-MS/MS in health products and transdermal patches. J Pharm Biomed Anal 2021; 201:114100. [PMID: 33957366 DOI: 10.1016/j.jpba.2021.114100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Revised: 04/20/2021] [Accepted: 04/22/2021] [Indexed: 11/15/2022]
Abstract
The spreading of narcotics especially illicit novel psychoactive substances is a continuing problem in recent years. In response to reduce the morbidity and crime related to fentanyl analogues, the accurate measurement of fentanyl analogues concentrations is significantly important in the analytical laboratories for customs checks and clinical application. In this work, ethyl acetate was selected as extraction solvent, 50 mg of PSA, 100 mg of C18, and 10 mg of GCB were optimized for purification. A modified QuEChERS extraction method followed by high performance liquid chromatography-tandem mass spectrometry with the mode of multiple reaction monitoring has been developed for the simultaneous determination of 20 fentanyl analogues in collagen peptides, slimming capsules and fentanyl transdermal patches. The limits of detection (LODs) varied from 0.004 to 0.02 μg L-1 with relative standard deviations of 4.89-11.4 % and showed good linearity in the range of 0.02-10 μg L-1 and 0.01-1.00 mg L-1, respectively. The recoveries for 20 fentanyl analogues in the low (at μg L-1 level) and high (at mg L-1 level) concentration spiked samples were in the range of 77.7-114 % and 83.9-116 %, which demonstrated the application potential of the proposed method for the determination of fentanyl analogues with low and high concentration in real case samples. In addition, the matrix effect and the cross-reactivity were also proved to not interfere with quantitation of targeted fentanyl analogues. Thus, the developed method showed high sensitivity and good accuracy, which makes it suitable for the rapid detection of fentanyl analogues for customs and border service as well as pharmaceuticals.
Collapse
Affiliation(s)
- Han Wang
- Wuhan Customs District of China, Wuhan, 430020, PR China.
| | - Xiaoya Zhao
- Wuhan Customs District of China, Wuhan, 430020, PR China
| | - Yinzhu Shang
- Wuhan Customs District of China, Wuhan, 430020, PR China
| | - Hui Wang
- Wuhan Customs District of China, Wuhan, 430020, PR China
| | - Peng Wang
- Wuhan Customs District of China, Wuhan, 430020, PR China
| | - Xiaoxiao Yu
- Hubei Key Laboratory of Pollutant Analysis & Reuse Technology, College of Chemistry and Chemical Engineering, Hubei Normal University, Huangshi, 435002, PR China.
| |
Collapse
|
12
|
Budelier MM, Franks CE, Farnsworth CW, Roper SM. Detecting Fentanyl Analogs in Urine Using Precursor Ion Scan Mode. J Anal Toxicol 2021; 46:bkab002. [PMID: 33416076 DOI: 10.1093/jat/bkab002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 12/15/2020] [Accepted: 01/07/2021] [Indexed: 01/14/2023] Open
Abstract
The opioid crisis has led many providers to inquire about the capabilities of urine drug testing to detect contemporary compounds such as fentanyl and fentanyl analogs. However, current methods for clinical urine drug testing, including immunoassays and targeted liquid chromatography tandem mass spectrometry, are not designed to broadly screen for the variety of fentanyl analogs that may be encountered. In this proof-of-principle study we developed a precursor ion scan method to enable semi-targeted data acquisition for structurally related fentanyl analogs. Based on the knowledge that many analogs fragment to m/z=188 and m/z=105, data was acquired on all precursor ions 250-400 Da that fragmented to these product ions. Using a tandem mass spectrometer we analyzed 102 residual urine specimens, in which we identified fentanyl, acetylfentanyl and acrylfentanyl. In 30 contrived urine samples, the precursor ion scan was also able to identify furanylfentanyl, butryrlfentanyl, 4-fluroisobutrylfentanyl, and despropionylfentanyl with accuracy ranging from 83-100%.
Collapse
Affiliation(s)
- Melissa M Budelier
- Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University, St. Louis, MO, USA
| | - Caroline E Franks
- Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University, St. Louis, MO, USA
| | - Christopher W Farnsworth
- Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University, St. Louis, MO, USA
| | - Stephen M Roper
- Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University, St. Louis, MO, USA
| |
Collapse
|
13
|
Recent bionalytical methods for the determination of new psychoactive substances in biological specimens. Bioanalysis 2020; 12:1557-1595. [PMID: 33078960 DOI: 10.4155/bio-2020-0148] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
One of the problems associated with the consumption of new psychoactive substances is that in most scenarios of acute toxicity the possibility of quick clinical action may be impaired because many screening methods are not responsive to them, and laboratories are not able to keep pace with the appearance of new substances. For these reasons, developing and validating new analytical methods is mandatory in order to efficiently face those problems, allowing laboratories to be one step ahead. The goal of this work is to perform a critical review regarding bionalytical methods that can be used for the determination of new psychoactive substances (phenylethylamines, cathinones, synthetic cannabinoids, opioids, benzodiazepines, etc), particularly concerning sample preparation techniques and associated analytical methods.
Collapse
|
14
|
Adamowicz P, Bakhmut Z, Mikolajczyk A. Screening procedure for 38 fentanyl analogues and five other new opioids in whole blood by liquid chromatography‐tandem mass spectrometry. J Appl Toxicol 2020; 40:1033-1046. [DOI: 10.1002/jat.3962] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2019] [Revised: 01/27/2020] [Accepted: 02/12/2020] [Indexed: 12/28/2022]
|